The first one, between the 1990s and the turn of 2000, was more focused on the role of P16 inactivation as a step toward cancer progression, and the second phase, which started around the mid-2000s, was more focused on the role of p16ink4a as a surrogate marker of HPV infection and on the role of its overexpression. Here, CDKN2A is linked to cancer.